logo-loader

Alnylam Pharma's shares leap as it reveals positive results from late-stage trial for a hereditary disease treatment

Last updated: 12:20 20 Sep 2017 EDT, First published: 03:19 20 Sep 2017 EDT

Drug test
About 50,000 people worldwide suffer from the disease, which currently has no approved treatment apart from liver transplant

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) saw its shares leap over 20% in pre-market trading after the drugs firm and its French partner Sanofi SA revealed positive results from a late-stage trial of a treatment for Hereditary ATTR (hATTR) Amyliodosis patients with polyneuropathy.

In a joint statement, the companies said an investigational RNAi therapeutic met its primary and secondary endpoints.

The disease is an inherited one that is progressively debilitating and often fatal and is caused by mutations in the TTR gene - TTR protein is produced in the liver and usually acts as a carrier for vitamin A.

Significant milestone

About 50,000 people worldwide suffer from the disease, which currently has no approved treatment apart from liver transplant.

Elias Zerhouni, president, global R&D at Sanofi said: “This is a significant milestone that supports our belief that RNAi therapeutics have the potential to become an innovative new class of medicines for patients with rare genetic diseases."

In pre-market trading in New York,  Alnylam shares were up nearly 22% at US$91.53. 

Later they gained over 35% to stand at US$101.87 each.

Ramp Metals Launches Drilling Program in Pursuit of High-Grade Nickel in...

Ramp Metals CEO Jordan Black joined Steve Darling from Proactive to introduce the company to the public domain and share exciting developments in the mining industry. With a background as a geotechnical engineer and experience in venture capital, including a notable role in taking GoldSpot...

1 hour, 1 minute ago